1
|
Abstract
This article is a short version of a report which presents a comprehensive analysis of clinical trials and publications examining the value of cytotoxic chemotherapy in the treatment of advanced epithelial cancer. As a result of the analysis and the comments received from hundreds of oncologists in reply to a request for information, the following facts can be noted. Apart from lung cancer, in particular small-cell lung cancer, there is no direct evidence that chemotherapy prolongs survival in patients with advanced carcinoma. Except for ovarian cancer, available indirect evidence rather supports the absence of a positive effect. In treatment of lung cancer and ovarian cancer, the therapeutical benefit is at best rather small, and a less aggressive treatment seems to be at least as effective as the usual one. It is possible that certain sub-groups of patients benefit from the treatment, yet so far the available results do not allow a sufficiently precise definition of these groups. Many oncologists take it for granted that response to therapy prolongs survival, an opinion which is based on a fallacy and which is not supported by clinical studies. To date, it is unclear whether the treated patients, as a whole, benefit from chemotherapy as to their quality of life. For most cancer sites, urgently required types of studies such as randomized de-escalations of dose or comparisons of immediate versus deferred chemotherapy are still lacking. With few exceptions, there is no good scientific basis for the application of chemotherapy in symptom-free patients with advanced epithelial malignancy.
Collapse
Affiliation(s)
- U Abel
- Tumorzentrum Heidelburg/Mannheim, Germany
| |
Collapse
|
2
|
Stockdale AD, Rostom AY. Upper-half body irradiation for oat cell carcinoma of the bronchus. Br J Radiol 1989; 62:563-4. [PMID: 2544242 DOI: 10.1259/0007-1285-62-738-563] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Affiliation(s)
- A D Stockdale
- Regional Centre for Radiotherapy and Oncology, St Luke's Hospital, Guildford, Surrey
| | | |
Collapse
|
3
|
McVie JG, Dalesio OB, van Tinteren H. Small cell lung cancer. Acta Oncol 1989; 28:729-41. [PMID: 2556169 DOI: 10.3109/02841868909092304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- J G McVie
- Department of Clinical Research, Netherlands Cancer Institute, Amsterdam, Holland
| | | | | |
Collapse
|
4
|
Vicini F, Decker D, Martinez A. The Role of External Beam Radiotherapy in the Treatment of Small-Cell Lung Cancer. Hematol Oncol Clin North Am 1988. [DOI: 10.1016/s0889-8588(18)30602-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
5
|
Johnson DH, Greco FA. Treatment of small cell lung cancer: another study on alternating chemotherapy. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY 1987; 23:1577-9. [PMID: 2828068 DOI: 10.1016/0277-5379(87)90433-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
6
|
Brincker H, Hindberg J, Hansen PV. Cyclic alternating polychemotherapy with or without upper and lower half-body irradiation in small cell anaplastic lung cancer. A randomized study. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY 1987; 23:205-11. [PMID: 2832178 DOI: 10.1016/0277-5379(87)90016-2] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Ninety-six patients with small cell anaplastic lung carcinoma were given monthly chemotherapy with vincristine-doxorubicin-cyclophosphamide alternating with CCNU-methotrexate-etoposide for 18 months or until evidence of progressive disease. Forty-four patients were randomized to chemotherapy alone and 52 patients to chemotherapy plus 600 cGy of both upper and lower half-body irradiation given day 60 and 100, respectively. In 78 evaluable patients surviving more than 100 days the overall response rate was identical in the two arms of the study, 68% vs. 66%. However, time to progression was significantly shorter in the irradiated patients (P = 0.05). Only 25% of the irradiated patients tolerated greater than or equal to 75% of the scheduled dose of chemotherapy, against 91% of the non-irradiated patients (P = 0.0001). Thus, half-body irradiation was associated with a shorter time to progression and a decreased ability to give maintenance chemotherapy at proposed doses.
Collapse
Affiliation(s)
- H Brincker
- Department of Oncology and Radiotherapy, Odense University Hospital, Denmark
| | | | | |
Collapse
|
7
|
Abstract
To assess the results of therapeutic advances in the treatment of small cell carcinoma of the lung (SCCL) achieved during the past 15-year period at a single large institution, 508 patients treated between 1968 and 1982 were divided into two groups: 157 patients (66 in the category of limited-stage disease and 91 in the extensive-stage disease category) treated with low-dose small-volume radiotherapy (RT) (time dose fractionation [TDF] 49-66) and with cyclophosphamide alone or a COPP program during the first period of 7 years (1968-1974); 351 patients (180 in limited and 171 in extensive stage) treated with multidrug chemotherapy (CT) and high-dose large-volume RT (TDF 73-89) during the second period of 8 years (1975-1982). For patients with limited-stage cancer, 5-year actuarial survivals were 3% versus 7% for the periods 1968-1974 versus 1975-1982, respectively, P less than 0.01. For patients with extensive-stage cancer, the median survival time (MST) and 2-year actuarial survivals were 5 months and 2% versus 7 months and 4% for the periods 1968-1974 versus 1975-1982, respectively. To evaluate the outcome of a contemporary approach, i.e., CT alone, with RT reserved for locoregional failure, 180 patients with limited-stage cancer who were treated (1975-1982) were further analyzed for MST, 2- and 5-year actuarial survival figures, and local-tumor control rates according to the therapeutic approaches employed: CT + RT (112); CT alone (36); RT alone (17); and surgery (S) +/- CT +/- RT (15). Although the 36 patients in CT alone seems a small number, 17 of the 36 patients were enrolled in this approach in 1981-1982, reflecting a shift of emphasis from RT to CT. The MST and 2-year actuarial survival figures were 11 months and 0% versus 13 months and 21% for CT alone versus CT + RT respectively, P less than 0.05. CT + RT achieved a 5-year cure rate of 8%. S +/- CT +/- RT or RT alone also achieved 5-year cure rates of 8% and 10.5%, respectively, in selected subsets of patients. Local relapse rates were 80% (29/36) versus 25% (28/112) for CT alone versus CT + RT. These data emphasize the importance of thoracic RT given at the early phase of treatment to improve long-term survival for patients with limited-stage SCCL.
Collapse
|
8
|
Powell BL, Jackson DV, Scarantino CW, Pope EK, Case LD, Choplin R, Richards F, Muss HB, Craig JB, Cruz JM. Sequential hemibody irradiation integrated into a chemotherapy-local radiotherapy program for limited disease small cell lung cancer. Int J Radiat Oncol Biol Phys 1986; 12:1951-6. [PMID: 3021692 DOI: 10.1016/0360-3016(86)90131-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Twenty-four patients with limited disease small cell lung cancer (SCLC) were treated with sequential hemibody irradiation (SHB) integrated into a conventional chemotherapy-local radiotherapy (LRT) program. Among 23 evaluable patients, 12 (52%) attained a complete response (CR) and 8 (35%) attained a partial response for an overall major response rate of 87%. The median time since study entry is 29 months. Durations of response are 9.9 months for all patients and 16.5 months for patients who achieved a CR. The primary site was the predominant area of recurrence. The median survival is 13.2 months for all patients and 23.2 months for the 12 patients who attained a CR. Myelosuppression, especially thrombocytopenia, was the major toxicity. Acute radiation toxicities and subacute pneumonitis previously associated with hemibody radiotherapy were well controlled or prevented using the current dose, premedication, and shielding techniques. This integrated program of systemic therapies with SHB and combination chemotherapy plus LRT is feasible for limited disease SCLC; it may prolong survival in patients who attain a CR but compared to similar programs without hemibody irradiation, there was no improvement in overall response rate, response duration, or survival.
Collapse
|
9
|
Urtasun R, Belch A, Bodnar D. Upper Half Body Irradiation in Small Cell Lung Cancer. Chest 1986. [DOI: 10.1378/chest.89.4_supplement.347s] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
10
|
Lichter AS, Bunn PA, Ihde DC, Cohen MH, Makuch RW, Carney DN, Johnston-Early A, Minna JD, Glatstein E. The role of radiation therapy in the treatment of small cell lung cancer. Cancer 1985; 55:2163-75. [PMID: 2983875 DOI: 10.1002/1097-0142(19850501)55:9+<2163::aid-cncr2820551420>3.0.co;2-y] [Citation(s) in RCA: 35] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Patients with small cell lung cancer (SCLC) are candidates for aggressive therapy because of their potential for long-term survival, especially patients with limited-stage disease. Although no treatment protocol can be considered "standard", the best results in limited-stage SCLC appear to be produced by a combination of chemotherapy and thoracic irradiation. Ongoing protocols testing the efficacy of thoracic irradiation should be able to settle question of the optimal treatment approach in limited-stage SCLC over the next 1 to 2 years. Careful attention to volume treated and the use of shrinking fields produce the best results with the minimum of toxicity. Treatment of extensive-stage SCLC has not been substantially improved to date with the addition of local or systemic irradiation. Prophylactic cranial irradiation reduces the incidence of CNS failure in SCLC and should be given, at a minimum, to patients achieving complete response status. Whether patients with partial response should also receive prophylactic cranial irradiation remains controversial. Finally, half-body radiation in SCLC is an experimental research technique that has shown some promise but remains quite toxic when combined with systemic chemotherapy.
Collapse
|
11
|
Powell BL, Jackson DV, Scarantino CW, Pope E, Choplin R, Craig JB, Atkins JN, Cooper MR, Hopkins JO, McMahan R, Muss HB, Richards F, Stuart JJ, White DR, Zekan P, Spurr CL, Capizzi RL. Sequential hemibody and local irradiation with combination chemotherapy for small cell lung carcinoma: a preliminary analysis. Int J Radiat Oncol Biol Phys 1985; 11:457-62. [PMID: 2982771 DOI: 10.1016/0360-3016(85)90175-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Sequential hemibody irradiation (SHB) was integrated with combination chemotherapy and local irradiation (LRT) in the induction and consolidation phases of a therapeutic protocol for small cell lung carcinoma (SCLC). Forty-one previously untreated patients were entered into this program. Among 38 evaluable patients (20 with limited disease [LD] and 18 with extensive disease [ED], the overall response rate was 63% (90% in LD and 33% in ED patients). The estimated overall survival is 8.1 months. The major toxicity has been myelosuppression--especially thrombocytopenia. The frequency of previously described "acute radiation syndromes" and radiation pneumonitis associated with hemibody irradiation have been substantially decreased at the current dosage with premedication and shielding techniques. The integration of SHB as a systemic therapy with combination chemotherapy and LRT is a feasible program for sequential administration of non-cross-resistant agents in SCLC and may be beneficial in patients with limited disease.
Collapse
|
12
|
Bleehen NM, Jones DH. The role of radiotherapy in the management of small cell bronchogenic carcinoma. Recent Results Cancer Res 1985; 97:116-26. [PMID: 2581290 DOI: 10.1007/978-3-642-82372-5_11] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
13
|
Van Houtte P, Salazar OM, Henry J. Radiotherapy in non-small cell lung cancer: present progress and future perspectives. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY 1984; 20:997-1006. [PMID: 6432542 DOI: 10.1016/0277-5379(84)90100-7] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
14
|
Morstyn G, Ihde DC, Lichter AS, Bunn PA, Carney DN, Glatstein E, Minna JD. Small cell lung cancer 1973-1983: early progress and recent obstacles. Int J Radiat Oncol Biol Phys 1984; 10:515-39. [PMID: 6327578 DOI: 10.1016/0360-3016(84)90032-4] [Citation(s) in RCA: 155] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
The recognition that the vast majority of patients with small cell lung cancer have distant metastatic disease at the time of diagnosis led to the use of systemic chemotherapy and consequent major improvements in survival in the early to mid-1970's. In the past five years, however, the pace of therapeutic advances has slowed. Recently evaluated treatment strategies, including more intensive induction chemotherapy, "late intensive" therapy of responding patients, alternation of chemotherapeutic regimens, integration of chest irradiation with drug therapy, large field irradiation, and reappraisal of the value of surgical resection, are discussed in this review. Advances in understanding of the cell biology of small cell lung cancer which may eventually lead to new forms of treatment are summarized.
Collapse
|
15
|
Spiro SG. Lung cancer--areas of progress. Postgrad Med J 1984; 60:218-24. [PMID: 6324154 PMCID: PMC2417786 DOI: 10.1136/pgmj.60.701.218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
16
|
Geddes DM, Spiro SG, Tobias JS, Souhami RL, Harper PG. Lung cancer: future prospects. Recent Results Cancer Res 1984; 92:118-27. [PMID: 6377418 DOI: 10.1007/978-3-642-82218-6_11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
17
|
|
18
|
Hansen HH, Elliott JA. Patterns of failure in small cell lung cancer: implications for therapy. Recent Results Cancer Res 1984; 92:43-57. [PMID: 6330810 DOI: 10.1007/978-3-642-82218-6_4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
19
|
Urtasun RC, Belch A, Bodnar D. Hemibody radiation, an active therapeutic modality for the management of patients with small cell lung cancer. Int J Radiat Oncol Biol Phys 1983; 9:1575-8. [PMID: 6313561 DOI: 10.1016/0360-3016(83)90332-2] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
In a previously published paper, the results of a preliminary clinical trial comparing systemic radiation (upper and lower hemibody technique) versus systemic chemotherapy in the management of all stages of small cell lung cancer (SCLC), suggested that hemibody radiation (HBI) was as efficient as systemic chemotherapy, particularly for patients with early disease. We are now presenting the final results of the above trial. The two year survival has shown that as many patients in the HBI as in the chemotherapy arm have reached this endpoint. However, there is a difference in favor of chemotherapy on both the median and one year survival for those patients with advanced stages. Therefore, as of June 1981, we have initiated a study incorporating HBI as a consolidating-maintenance agent for patients with all stages of the disease who have received a 3 1/2 months induction systemic chemotherapy plus local chest irradiation. Up to date, 65 patients have been entered and our median survival for those who received the complete treatment is 62.5 weeks.
Collapse
|
20
|
|
21
|
El-Khatib E, Sharplin J, Battista J. The density of mouse lung in vivo following X irradiation. Int J Radiat Oncol Biol Phys 1983; 9:853-8. [PMID: 6863058 DOI: 10.1016/0360-3016(83)90011-1] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
The lungs of mice were irradiated with single X radiation doses of 5 to 14 Gy. Six weeks after irradiation, computed tomographic (CT) scans of the mice were performed at two-week intervals. Beyond 14 weeks after irradiation, the animals were scanned at 1-week intervals. The mice irradiated to 5 and 7 Gy exhibited no change in lung density, in comparison with the unirradiated lungs of control mice up to times of 48 weeks. The mice irradiated to doses of greater than 10 Gy exhibited marked increases in lung density at 15 weeks after irradiation. Increases in density followed a similar time course for these doses, but the magnitude of the density increase was dependent on the radiation dose. An interpretation of these findings in terms of radiation pneumonitis is presented, and the possibility of using CT to monitor lung density in radiotherapy patients is discussed.
Collapse
|